MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Axsome Therapeutics Inc

Closed

SectorHealthcare

107.41 -2.09

Overview

Share price change

24h

Current

Min

107.33

Max

109.38

Key metrics

By Trading Economics

Income

-10M

-75M

Sales

14M

119M

EPS

-1.54

Profit margin

-63.075

Employees

683

EBITDA

-10M

-71M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+58.81% upside

Dividends

By Dow Jones

Next Earnings

5 maj 2025

Market Stats

By TradingEconomics

Market Cap

-458M

5.8B

Previous open

109.5

Previous close

107.41

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Axsome Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 kwi 2025, 23:04 UTC

Top News

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 kwi 2025, 22:40 UTC

Major Market Movers

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 kwi 2025, 22:18 UTC

Acquisitions, Mergers, Takeovers

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 kwi 2025, 18:51 UTC

Acquisitions, Mergers, Takeovers

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 kwi 2025, 23:43 UTC

Market Talk

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 kwi 2025, 23:41 UTC

Market Talk

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 kwi 2025, 22:22 UTC

Acquisitions, Mergers, Takeovers

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 kwi 2025, 22:21 UTC

Acquisitions, Mergers, Takeovers

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 kwi 2025, 21:43 UTC

Top News
Earnings

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 kwi 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3 kwi 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 kwi 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 kwi 2025, 20:43 UTC

Market Talk

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 kwi 2025, 20:34 UTC

Top News

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 kwi 2025, 20:23 UTC

Top News

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 kwi 2025, 20:15 UTC

Acquisitions, Mergers, Takeovers

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 kwi 2025, 19:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 kwi 2025, 19:55 UTC

Market Talk

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 kwi 2025, 19:21 UTC

Market Talk

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 kwi 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 kwi 2025, 18:45 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 kwi 2025, 18:45 UTC

Market Talk

Gold Drops In Tariff Fallout -- Market Talk

3 kwi 2025, 18:39 UTC

Market Talk

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 kwi 2025, 18:38 UTC

Top News

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 kwi 2025, 18:30 UTC

Top News

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 kwi 2025, 18:20 UTC

Market Talk

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 kwi 2025, 18:18 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 kwi 2025, 18:17 UTC

Market Talk

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 kwi 2025, 18:04 UTC

Market Talk

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 kwi 2025, 17:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

Axsome Therapeutics Inc Forecast

Price Target

By TipRanks

58.81% upside

12 Months Forecast

Average 174.29 USD  58.81%

High 216 USD

Low 133 USD

Based on 17 Wall Street analysts offering 12 month price targets forAxsome Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

17 ratings

17

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

107 / 113.5Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Neutral Evidence

Long Term

Strong Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.